[caption id="attachment_9277" align="aligncenter" width="1079"] Press Release[/caption]

Sale to Juvis? Pharmaceuticals supports AstraZeneca?s strategy of focusing on pipeline of new medicines

AstraZeneca today announced that it has agreed to sell the commercial rights to?Arimidex?(anastrozole) and?Casodex?(bicalutamide) in a number of European, African and other countries¹?to Juvis? Pharmaceuticals. The medicines, used primarily to treat breast and prostate cancers, have lost their compound patent protection in these countries. AstraZeneca already divested the rights to both?Arimidex?and?Casodex?in the US in 2017. Dave Fredrickson, Executive Vice President, Oncology Business Unit, said: ?Arimidex?and?Casodex?are important established medicines and we are pleased that Juvis? Pharmaceuticals will now take on the work of making sure patients continue to have access to them. Today?s agreement is part of a broader strategy of reducing our portfolio of mature medicines to reallocate resources towards developing our pipeline of new medicines.? Financial considerations As there were no closing conditions to the divestment, the agreement became effective upon signing. Juvis? Pharmaceuticals has made an upfront payment of $181m to AstraZeneca and may also make future sales-contingent payments of up to $17m. Income arising from the upfront payment will be reported in AstraZeneca?s financial statements in the fourth quarter of 2019. Income from the upfront and any future payments will be reported within Other Operating Income & Expense. In 2018,?Arimidex?had sales of?$37m?in the countries covered by this agreement, while?Casodex?had sales of $24m.?The divestment does not change the Company?s financial guidance for 2019. About?Arimidex Arimidex?(anastrozole) is an aromatase inhibitor, indicated primarily for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and the treatment of advanced breast cancer in postmenopausal women with disease progression, following tamoxifen therapy. About?Casodex Casodex?(bicalutamide) is an androgen-receptor inhibitor, indicated for use in combination therapy with a luteinising hormone-releasing hormone analogue for the treatment of Stage D2 metastatic carcinoma of the prostate. About AstraZeneca AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit?astrazeneca.com?and follow the Company on Twitter?@AstraZeneca.